Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.

Abstract: A multicolor light-storing ceramic for fire-protection indication and a preparation method thereof are provided. The preparation method includes: adding a glass based raw material, a light-storing powder, a dispersant and an alumina powder into a granulator, adding water mixed with a pore-forming agent and then mechanically stirring for granulation; adding a plasticizer after the stirring of 4˜8 h, and continuing the stirring for 1˜3 h to thereby obtain a mixture; packing the mixture into a mold and performing tableting; demolding and obtaining a light-storing self-luminous quartz ceramic by drying and firing using a kiln; printing a pattern onto a surface of the ceramic and then curing to obtain a light-storing ceramic for indication sign.

Abstract: A preparation method for improving light efficiency and stability of light storing ceramics is provided. Calcium ethanol solution is added into titanium precursor solution firstly and oleic acid dispersant is added, pure water and the light storing powder are subsequently added to obtain a light-storing powder-calcium titanate gel, and dried, crushed and sieved to obtain xerogel powder. Glass matrix material, sieved xerogel powder and another dispersant are placed into a granulator, and directly mechanically stirred and granulated after adding pure water. A plasticizer is added after stirring 4˜8 h, and continuously stirred for 1˜3 h to obtain a mixture, pressing, drying and firing. Calcium titanate is manually introduced to protect the light-storing powder from hydrolysis or high-temperature oxidation. It can also change the propagation path of fluorescence inside ceramics, improve light absorption and fluorescence output efficiency and is conducive to ceramic molding.

Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.

Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.

Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.